Xenikos B.V.
Biotechnology Research
Nijmegen, Gelderland, Nl
6 employees
- Employees
- 6
Xenikos B.V. Overview
- Headquarters
- Nijmegen, Gelderland, Nl
- Phone Number
- Available in AeroLeads
- Website
- xenikos.com
- Industry
- Biotechnology Research
- Employees
- 6
- Founded
- 2009
- Funding
- 2.7M
- Company Email
- Available in AeroLeads
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Xenikos B.V.
Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
Xenikos B.V. Contact Details
Compare Similar Companies to Xenikos B.V.
Synthon
Pharmaceutical Manufacturing
Byondis
Pharmaceutical Manufacturing
Vaxxinova
Veterinary Services
LAVA Therapeutics N.V.
Biotechnology Research
Artemis Bioservices
Pharmaceutical Manufacturing
CimCure B.V.
Pharmaceutical Manufacturing
Khondrion
Pharmaceutical Manufacturing
NC Biomatrix B.V.
Biotechnology
Pedmed-NL
Research Services
Protinhi Therapeutics
Biotechnology